-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, researchers assessed the risk of autoneural neurodefunctional disorder syndrome associated with the 4-price HPV vaccine, including chronic fatigue syndrome, complex areaal pain syndrome, and positional erect titration syndrome.
This study, a population-based self-controlled case study, collected information from Danish female vaccination participants on autologic neurodefunction syndrome resulting from human papillomavirus vaccination, and in 2007-16, 869 female participants aged 10-44 had autologic neurodefunction syndrome.
of the study was the difference in the incidence of autologic neurodefurction syndrome between HPV vaccination and non-vaccinated populations.
a total of 869 patients with autologic neurodefunctional disorder syndrome were diagnosed during the follow-up year of 1058,1902 people, of whom 136 were chronic fatigue syndrome, 535 were complex regional pain syndrome and 198 were positional erect TSD syndrome.
In the 365 days after the four-price HPV vaccination, there was no significant increase in the risk of all autologic neurodefurction syndrome (ratio 0.99) or specific syndrome risk (chronic fatigue syndrome risk ratio of 0.38; complex area pain syndrome risk ratio of 1.31; and risk of erective TPD 0.86).
study that did not support the 4-price HPV vaccine increased the risk of autonitatic neurodefurction syndrome such as chronic fatigue syndrome, complex area pain syndrome, or positional erect titration syndrome in women.
.
